Collaboration in more than 46 countries.

You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.

NORTH AMERICA

Canada

United States

LATIN AMERICA

Argentina

Brazil

Mexico

Perú

GLOBAL

CEVA Global

EMEA (REGIONAL)

Denmark

Egypt

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Romania

South Africa

Spain

Sweden

Tunisia

Turkey

Ukraine

United Kingdom

ASIA PACIFIC

Asia Pacific (Regional)

CHINA

India

Indonesia

Japan

Korea

Malaysia

Philippines

Publications
PDF

Mucosiffa_Poster-1.pdf

Open PDF

Summary

Mucosiffa® (Ceva Santé Animale) is a modified-live vaccine (MLV) used for the control of bovine viral diarrhea virus (BVDV) infection. In pregnant heifers experimentally challenged by BVDV-1, one administration of Mucosiffa® 126 days before challenge had been proven to prevent fetal infection1. Because current practices in cattle farms favors yearly vaccination schedules, a new experiment was carried out to evaluate the level of fetal protection obtained in pregnant heifers challenged twelve months after one administration of Mucosiffa®.

Results demonstrate that Mucosiffa® is a safe MLV that provides 100% fetal protection to breeding females for at least one year after one intramuscular administration.

Share this publication:

Publication file:

Download publication
This site is registered on wpml.org as a development site.